A Phase 3 Global, Double-Blind, Randomized, Placebo???Controlled Study to Evaluate the Efficacy andSafety of ION-682884 in Patientswith Transthyretin???Mediated Amyloid Cardiomyopathy(ATTR CM)

Project: Research project

Project Details

Description

A Phase 3 Global, Double-Blind, Randomized, Placebo???Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin???Mediated Amyloid Cardiomyopathy (ATTR CM)
StatusActive
Effective start/end date6/1/216/30/24

Funding

  • IONIS PHARMACEUTICALS, INC.